retatrutide clinical trials update parkinson's disease trial drug therapies in the pipeline: 2024 Triple hormone receptor agonist retatrutide – retatrutide clinical trial dosing trials

The STEP 4 trial published in JAMA showed that participants maintained significant weight loss over 68 weeks when continuing the medication

We offer physician-led talks and events to help you learn more about how to deal with stress through movement, mindfulness, and refocusing

Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing

Before considering one, it is worth being clear-eyed: using IV glutathione to lighten skin is not a licensed medical treatment, the long-term safety evidence is limited, and several regulators have raised concerns

10.1136/bmj.324.7333.332 BMJ Br Med J

Zucconi B